Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Thomas Cluzeau, MD, PhD, Guillaume Robert, PhD, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Nicolas Mounier, MD, PhD, Jill Patrice Cassuto, MD, PhD, Lionel Ades, Sophie Raynaud, MD, PhD, Pierre Fenaux, MD, PhD, Patrick Auberger, PhD

Blood (2013) 122 (21): 1568.

https://doi.org/10.1182/blood.V122.21.1568.1568

Published: 2013

Journal Articles

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Thomas Cluzeau, MD, PhD, Nicolas Mounier, MD, PhD, Valentine Richez, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Henri Vinti, MD, Laurence Legros, MD, PhD, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Sophie Raynaud, Jill-Patrice Cassuto, MD

Blood (2012) 120 (21): 2813.

https://doi.org/10.1182/blood.V120.21.2813.2813

Published: 2012

Journal Articles

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

Laurence Legros, MD, PhD, Nathalie Ebran, PhD, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Nicolas Mounier, MD, PhD, Henri Vinti, MD, Jill-Patrice Cassuto, MD, Pierre-Simon Rohrlich, MD, PhD, Anne-Odile Hueber, PhD

Blood (2012) 120 (21): 4428.

https://doi.org/10.1182/blood.V120.21.4428.4428

Published: 2012

Journal Articles

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

Thomas Cluzeau, MD, PhD, Chimène Moreilhon, Nicolas Mounier, MD, PhD, Jean-Michel Karsenti, MD, Lionel Mannone, MD, Faezeh Legrand, MD, PhD, Valentine Richez, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud

Blood (2012) 120 (21): 4936.

https://doi.org/10.1182/blood.V120.21.4936.4936

Published: 2012

Journal Articles

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Thomas Cluzeau, MD, PhD, Guillaume Robert, Jean-Michel Karsenti, MD, Frederic Luciano, Alexandre Puissant, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Aline Renneville, MD, Claude Preudhomme, Pierre Fenaux, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud, Nicolas Mounier, MD, PhD, Patrick Auberger, MD, PhD

Blood (2012) 120 (21): 701.

https://doi.org/10.1182/blood.V120.21.701.701

Published: 2012

Journal Articles

Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines

Thomas Cluzeau, Guillaume Robert, Jean-Michel Karsenti, Frederic Luciano, Alexandre Puissant, S. Dominique Raynaud, MD, Lionel Mannone, Jill-Patrice Cassuto, Nicolas Mounier, Patrick Auberger

Blood (2010) 116 (21): 1817.

https://doi.org/10.1182/blood.V116.21.1817.1817

Published: 2010

Journal Articles

Correlation Between Outcome and Genetic Abnormalities Identified by High-Density Single Nucleotide Polymorphism Array Analysis In Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multi-Lineage Dysplasia Treated with Azacitidine

Thomas Cluzeau, Chimène Moreilhon, Nicolas Mounier, Jean-Michel Karsenti, Lionel Mannone, Henri Vinti, Laurence Legros, MD, Antoine Thyss, Georges Garnier, Jean Gutnecht, Daniel Re, MD, Patrick Auberger, Jill-Patrice Cassuto, S. Dominique Raynaud, MD

Blood (2010) 116 (21): 2929.

https://doi.org/10.1182/blood.V116.21.2929.2929

Published: 2010

Journal Articles

Preliminary Results Concerning the Prognosis Value of Vascular Endothelial Growth Factor (VEGF) in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Laurence Legros, MD, PhD, Sebastien Huault, Francois-Xavier Mahon, MD PhD, Anne-Odile Hueber, PhD, Irit Touitou, Jill-Patrice Cassuto, MD, Joelle Guilhot, Claude Peudhomme, MD PhD

Blood (2006) 108 (11): 4763.

https://doi.org/10.1182/blood.V108.11.4763.4763

Published: 2006

Journal Articles

Hypophosphatemia Observed in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate (Gleevec®) Is Related to Digestive Side-Effects.

Laurence Legros, MD, PhD, Veronique Breuil, MD PHD, Patricia Ferrari, MD, Jean Testa, MD PHD, Jill-Patrice Cassuto, MD

Blood (2006) 108 (11): 4765.

https://doi.org/10.1182/blood.V108.11.4765.4765

Published: 2006

Journal Articles

Pharmacological Blockade of NF-kB with AS602868, a Potent Small Molecule Inhibitor of IKK2 Leads to Apoptosis of Sensitive and Resistant Chronic Myeloid Leukemia Cells.

Veronique Imbert, PhD, Nadege Gonthier, PhD, Catherine Frelin, PhD, Nicolas Sirvent, MD, Michael Hummelsberger, MD, Anne Sirvent von Bueltzingsloewen, MD, Jill-Patrice Cassuto, MD, Francois-Xavier Mahon, MD, Philippe Rousselot, MD, Michel Dreano, PhD, Jean-Francois Peyron, PhD

Blood (2005) 106 (11): 2882.

https://doi.org/10.1182/blood.V106.11.2882.2882

Published: 2005

Journal Articles

Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia

Laurence Legros, Christine Bourcier, Arnaud Jacquel, François-Xavier Mahon, Jill-Patrice Cassuto, Patrick Auberger, Gilles Pagès

Blood (2004) 104 (2): 495–501.

https://doi.org/10.1182/blood-2003-08-2695

Published: 2004

NARROW

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Tyrosine Kinase Inhibitor-Mediated Apoptosis Is Potentiated by FasL and Increased with IFN-α in Chronic Myeloid Leukemia

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines

Correlation Between Outcome and Genetic Abnormalities Identified by High-Density Single Nucleotide Polymorphism Array Analysis In Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia with Multi-Lineage Dysplasia Treated with Azacitidine

Preliminary Results Concerning the Prognosis Value of Vascular Endothelial Growth Factor (VEGF) in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate.

Hypophosphatemia Observed in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate (Gleevec®) Is Related to Digestive Side-Effects.

Pharmacological Blockade of NF-kB with AS602868, a Potent Small Molecule Inhibitor of IKK2 Leads to Apoptosis of Sensitive and Resistant Chronic Myeloid Leukemia Cells.

Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only